Ligand Pharmaceuticals Earnings
NASDAQ: LGNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Thu, Nov 5, 2026
Fiscal period
Sep/2026
EPS estimate
$1.42
Ligand Pharmaceuticals earnings summary
Ligand Pharmaceuticals is scheduled to report Sep/2026 earnings on Nov 5, 2026, with analysts expecting EPS of $1.42. In its most recent report on Aug 7, 2026 (Q2 2026), LGND posted EPS of $2.22. Revenue for the quarter was $63.7 million.
Quarterly EPS is up 825.0% from the same quarter a year earlier. Across the last 16 reports, LGND shares moved an average of 3.4% (in either direction) in the first trading session after results, rising 6 times and falling 10 times.
Summary generated from market data by MetaCap's automated system. Methodology
LGND earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 7, 2026 | — | $2.22 | — | +0.5% |
| May 8, 2026 | — | $-0.67 | — | -3.7% |
| Feb 27, 2026 | — | $2.42 | — | +1.8% |
| Nov 7, 2025 | — | $5.68 | — | -0.8% |
| Aug 8, 2025 | — | $0.24 | — | +0.7% |
| May 9, 2025 | — | $-2.21 | — | +0.1% |
| Feb 28, 2025 | — | $-1.70 | — | -6.1% |
| Nov 8, 2024 | — | $-0.39 | — | -7.9% |
| Aug 7, 2024 | — | $-2.88 | — | +2.0% |
| May 8, 2024 | — | $4.75 | — | -1.4% |
| Feb 29, 2024 | — | $1.07 | — | -6.3% |
| Nov 9, 2023 | — | $-0.59 | — | +4.4% |
| Aug 9, 2023 | — | $0.13 | — | -1.5% |
| May 8, 2023 | — | $2.33 | — | -1.7% |
| Feb 28, 2023 | — | $-1.04 | — | -11.3% |
| Nov 8, 2022 | — | $0.02 | — | -5.0% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.